ライフサイエンスコーパス: chronic granulomatous disease

1 hancing the oxidative burst in patients with chronic granulomatous disease.

2 nts with primary immunodeficiency other than chronic granulomatous disease.

3 rms of severe combined immune deficiency and chronic granulomatous disease.

4 sed association of autoimmune disorders with chronic granulomatous disease.

5 id organ transplantation, advanced AIDS, and chronic granulomatous disease.

6 and association of autoimmune diseases with chronic granulomatous disease.

7 patches from eosinophils from a patient with chronic granulomatous disease.

8 and neutrophils from a patient with X-linked chronic granulomatous disease.

9 e of antifungal agents in the prophylaxis of chronic granulomatous disease.

10 novel approach in the molecular treatment of chronic granulomatous disease.

11 hylaxis against serious fungal infections in chronic granulomatous disease.

12 em cells derived from patients with X-linked chronic granulomatous disease.

13 organisms known to have unusual virulence in chronic granulomatous disease.

14 f gene therapy protocols being developed for chronic granulomatous disease.

15 into the X-linked gene CYBB, thereby causing chronic granulomatous disease.

16 tracts of patients with cystic fibrosis and chronic granulomatous disease.

17 ents suffering from cystic fibrosis (CF) and chronic granulomatous disease.

18 gp91(phox)) gives rise to the known types of chronic granulomatous disease.

19 promoter have been detected in patients with chronic granulomatous disease.

20 r in stimulated monocytes from patients with chronic granulomatous disease.

21 ne deficiency, Wiskott-Aldrich syndrome, and chronic granulomatous disease.

22 nia or phagocyte functional defects, such as chronic granulomatous disease.

23 h defective ROS production machinery develop chronic granulomatous disease.

24 cess caused by a Phellinus sp. in a boy with chronic granulomatous disease.

25 e and efficacious in high-risk patients with chronic granulomatous disease.

26 ng dectin-1 deficiency, CARD9 deficiency, or chronic granulomatous disease.

27 ytic functions, such as the genetic disorder chronic granulomatous disease.

28 ealthy volunteers with that in patients with chronic granulomatous disease.

29 is a predictor of survival in patients with chronic granulomatous disease.

30 might be linked to survival in patients with chronic granulomatous disease.

31 ents with X-linked (NOX2) or autosomal (p47) chronic granulomatous disease.

32 nt genetic defect causing p47-phox-deficient chronic granulomatous disease (A47 degrees CGD) is a GT

33 In the genetic disorder chronic granulomatous disease, absent oxidase function i

34 In chronic granulomatous disease allogeneic haemopoietic st

35 Chronic granulomatous disease, an inherited disorder of

36 ents of this complex have been implicated in chronic granulomatous disease and Crohn's disease, highl

37 ble morbidity and mortality in patients with chronic granulomatous disease and cystic fibrosis.

38 unctive therapy in genetic disorders such as chronic granulomatous disease and infectious diseases su

39 Chronic granulomatous disease and leukocyte adhesion def

40 advances in development of gene therapy for chronic granulomatous disease and leukocyte adhesion def

41 Patients with chronic granulomatous disease and modest residual produc

42 th brain abscess formation in a patient with chronic granulomatous disease and review the literature

43 n conducted for other forms of PID including chronic granulomatous disease and Wiskott-Aldrich syndro

44 r X-linked severe combined immunodeficiency, chronic granulomatous disease, and other diseases.

45 educes the frequency of fungal infections in chronic granulomatous disease, but monitoring for long-t

46 Patients with chronic granulomatous disease can develop chronic granul

47 intermediates (ROIs) is the major defect in chronic granulomatous disease, causing recurrent infecti

48 ying immunocompromising condition, including chronic granulomatous disease (CGD) (n=4), diabetes mell

49 The rarer PID patients without chronic granulomatous disease (CGD) achieved an OS at 3

50 athway is involved in the pathophysiology of chronic granulomatous disease (CGD) and sepsis.

51 ties in circulating B cells in patients with chronic granulomatous disease (CGD) and those with HIV i

52 xhibits a phenotype similar to that of human chronic granulomatous disease (CGD) and, thus, is an exc

53 Liver abscesses in chronic granulomatous disease (CGD) are typically diffic

54 utation in p47-phox-deficient (A47 degrees ) chronic granulomatous disease (CGD) as a result of the i

55 Chronic granulomatous disease (CGD) can be cured by allo

56 Chronic granulomatous disease (CGD) can result from any

57 Defective neutrophils in patients with chronic granulomatous disease (CGD) cause susceptibility

58 Data from a registry of 368 patients with chronic granulomatous disease (CGD) documenta shift in t

59 monstrated in human patients who suffer from chronic granulomatous disease (CGD) due to defective NAD

60 Patients with chronic granulomatous disease (CGD) exhibit deficient ge

61 Patients with chronic granulomatous disease (CGD) experience immunodef

62 onuclear leukocytes (PMN) from patients with chronic granulomatous disease (CGD) fail to produce micr

63 ls are reduced in the blood of patients with chronic granulomatous disease (CGD) for reasons and cons

64 Mice with X-linked chronic granulomatous disease (CGD) generated by targete

65 Although prognosis of Chronic Granulomatous Disease (CGD) has greatly improved

66 Patients with chronic granulomatous disease (CGD) have a mutated NADPH

67 ans first described the clinical features of chronic granulomatous disease (CGD) in 1959.

68 than 6 years of age) often resembles that of chronic granulomatous disease (CGD) in extent and featur

69 Chronic granulomatous disease (CGD) is a genetic disorde

70 Chronic granulomatous disease (CGD) is a group of inheri

71 Chronic granulomatous disease (CGD) is a hereditary diso

72 Chronic granulomatous disease (CGD) is a primary immune

73 Chronic granulomatous disease (CGD) is a primary immunod

74 Chronic granulomatous disease (CGD) is a primary immunod

75 Chronic granulomatous disease (CGD) is a primary immunod

76 Chronic granulomatous disease (CGD) is a primary immunod

77 Chronic granulomatous disease (CGD) is a rare congenital

78 Chronic granulomatous disease (CGD) is a rare genetic di

79 Chronic granulomatous disease (CGD) is a rare genetic di

80 Chronic granulomatous disease (CGD) is a rare inherited

81 Chronic granulomatous disease (CGD) is a rare phagocytic

82 Chronic granulomatous disease (CGD) is a rare primary im

83 Chronic granulomatous disease (CGD) is an inherited defi

84 Chronic granulomatous disease (CGD) is an inherited dise

85 Chronic granulomatous disease (CGD) is an inherited diso

86 Chronic granulomatous disease (CGD) is an inherited diso

87 Chronic granulomatous disease (CGD) is an inherited diso

88 Chronic granulomatous disease (CGD) is an inherited hema

89 Chronic granulomatous disease (CGD) is an inherited immu

90 Chronic granulomatous disease (CGD) is an inherited immu

91 invasive aspergillosis (IA) in patients with chronic granulomatous disease (CGD) is Aspergillus fumig

92 Chronic granulomatous disease (CGD) is associated with s

93 Chronic granulomatous disease (CGD) is characterized by

94 Chronic granulomatous disease (CGD) is characterized by

95 Chronic granulomatous disease (CGD) is characterized by

96 Chronic granulomatous disease (CGD) is due to defective

97 Immunodeficiency in chronic granulomatous disease (CGD) is well characterize

98 NADPH oxidase 2 (Nox2)-deficient chronic granulomatous disease (CGD) mice that lack the g

99 PB in normal volunteers and in patients with chronic granulomatous disease (CGD) or adenosine deamina

100 ogically inhibited oxidase, or isolated from chronic granulomatous disease (CGD) patients and mice, f

101 Chronic granulomatous disease (CGD) patients are suscept

102 Chronic granulomatous disease (CGD) patients have recurr

103 eotide phosphate (NADPH) oxidase predisposes chronic granulomatous disease (CGD) patients to infectio

104 inucleotide (NADPH) oxidase in patients with chronic granulomatous disease (CGD) results in susceptib

105 utrophils and neutrophils from patients with chronic granulomatous disease (CGD) that are completely

106 uency of serious infections in patients with chronic granulomatous disease (CGD) through an unknown m

107 is a Gram-negative pathogen in patients with chronic granulomatous disease (CGD), a deficiency in the

108 altered B cell compartment in patients with chronic granulomatous disease (CGD), a disorder of phago

109 during prolonged neutropenia or in cases of chronic granulomatous disease (CGD), a primary immunodef

110 de phosphate oxidase 2 (NOX2) function cause chronic granulomatous disease (CGD), a primary immunodef

111 e a major threat for patients suffering from chronic granulomatous disease (CGD), a primary immunodef

112 egative bacterium that infects patients with chronic granulomatous disease (CGD), a primary immunodef

113 n of either p22(phox) or gp91(phox) leads to chronic granulomatous disease (CGD), a severe immune dis

114 ox), both of which are mouse models of human chronic granulomatous disease (CGD), also lack LTP.

115 Chronic granulomatous disease (CGD), an immunodeficiency

116 Progress in development of gene therapy for chronic granulomatous disease (CGD), an inherited defect

117 uilding stem cell transplants, patients with chronic granulomatous disease (CGD), and others.

118 nactivating mutations in this enzyme lead to chronic granulomatous disease (CGD), associated with inc

119 ntation (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and

120 In chronic granulomatous disease (CGD), defective phagocyti

121 t p40(phox), have been described in cases of chronic granulomatous disease (CGD), defining their esse

122 id (BALF) and lungs of A. fumigatus-infected chronic granulomatous disease (CGD), hydrocortisone-trea

123 t in PMNs from six individuals with X-linked chronic granulomatous disease (CGD), p47phox and p67phox

124 a respiratory burst, ie, from a patient with chronic granulomatous disease (CGD), was strongly inhibi

125 so referred to as NOX2), are associated with chronic granulomatous disease (CGD), which is characteri

126 Mutations in gp91(phox) result in chronic granulomatous disease (CGD), which is diagnosed

127 e was recovered, leading to the diagnosis of chronic granulomatous disease (CGD).

128 (SCID), Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD).

129 subunit is the site of mutations in X-linked chronic granulomatous disease (CGD).

130 rgillosis is a major threat to patients with chronic granulomatous disease (CGD).

131 ly that has been isolated from patients with chronic granulomatous disease (CGD).

132 ensis, an emerging pathogen in patients with chronic granulomatous disease (CGD).

133 ions in people with cystic fibrosis (CF) and chronic granulomatous disease (CGD).

134 ndividuals with the primary immunodeficiency chronic granulomatous disease (CGD).

135 are the basis for the human immunodeficiency chronic granulomatous disease (CGD).

136 Genetic defects in NADPH oxidase (chronic granulomatous disease [CGD]) and corticosteroid-

137 -deficient, and respiratory burst-deficient (chronic granulomatous disease [CGD]) neutrophils killed

138 deficiencies in the oxidative burst seen in chronic granulomatous disease, could lead to pathologic

139 nied with Duchenne muscular dystrophy (DMD), chronic granulomatous disease (CYBB), retinitis pigmento

140 A 28-year-old man with chronic granulomatous disease developed worsening respir

141 of a lesion at the RP3 locus, in addition to chronic granulomatous disease, Duchenne muscular dystrop

142 Sarcoidosis is a chronic granulomatous disease for which there are limite

143 of illness and death among 287 patients with chronic granulomatous disease from 244 kindreds.

144 A mouse model for chronic granulomatous disease has been developed and pro

145 neficial gene therapy correction of X-linked chronic granulomatous disease in two adult patients was

146 d in neutrophils isolated from patients with chronic granulomatous disease incubated with a caspase i

147 Chronic granulomatous disease is a rare disorder in whic

148 Chronic granulomatous disease is a rare inherited disord

149 Chronic granulomatous disease is a rare inherited primar

150 Chronic granulomatous disease is an inherited immune def

151 Chronic granulomatous disease is caused by missense, non

152 Chronic granulomatous disease is the manifestation of ge

153 However, chronic granulomatous disease neutrophils, which do not

154 Sarcoidosis is a chronic granulomatous disease of unknown etiology.

155 ditions such as Wiskott-Aldrich syndrome and chronic granulomatous disease, offering curative engraft

156 , p40(phox), p47(phox), p67(phox) (autosomal chronic granulomatous disease), or gp91(phox) (X-linked

157 ns, which compromise p40(phox) function in a chronic granulomatous disease patient, also perturbed cl

158 ad no effect on endothelial function in NOX2-chronic granulomatous disease patients (-0.9; 95% confid

159 -mediated dilatation was not observed in p47-chronic granulomatous disease patients (-1.5%; 95% confi

160 Neutrophils from chronic granulomatous disease patients and Lyn -/- mice

161 H(+) currents in granulocytes from X-linked chronic granulomatous disease patients lacking gp91(phox

162 he reduced Mo-DC differentiation observed in chronic granulomatous disease patients lacking p22phox.

163 p1 is normally activated in neutrophils from chronic granulomatous disease patients that lack cytochr

164 The response to IR in chronic granulomatous disease patients was compared with

165 Additionally, neutrophils from chronic granulomatous disease patients, carrying mutatio

166 e to compromise antifungal immune control in chronic granulomatous disease patients.

167 While sarcoidosis is a chronic granulomatous disease presumably reflecting an e

168 tients with the p47(phox) deficiency form of chronic granulomatous disease received intravenous infus

169 graft is a feasible option for patients with chronic granulomatous disease, recurrent life-threatenin

170 rors of the phagocyte NADPH oxidase complex (chronic granulomatous disease), severe congenital neutro

171 atus of gene therapy for immunodeficiencies, chronic granulomatous disease, suicide gene therapy for

172 Mice with chronic granulomatous disease that were infected with B.

173 ent (p47(phox-/-)) mice are a model of human chronic granulomatous disease; these mice are prone to d

174 ciency (SCID), Wiskott-Aldrich syndrome, and chronic granulomatous disease through retrospective, pro

175 ulomas and the susceptibility of humans with chronic granulomatous disease to mycobacterial infection

176 atients, five children and five adults, with chronic granulomatous disease underwent peripheral-blood

177 Survival of patients with chronic granulomatous disease was strongly associated wi

178 Using Transwells and cells of patients with chronic granulomatous disease, we show that this downreg

179 Patients aged 0-40 years with chronic granulomatous disease were assessed and enrolled

180 s (median age 12.7 years; IQR 6.8-17.3) with chronic granulomatous disease were enrolled from June 15

181 nulomatous disease), or gp91(phox) (X-linked chronic granulomatous disease), which result in variable

182 ecies (ROS) because cells from patients with chronic granulomatous disease, which are defective in RO

183 donium and in neutrophils from patients with chronic granulomatous disease, which lack NADPH oxidase.

184 This was also observed in individuals with chronic granulomatous disease, who lack NADPH oxidase ac

185 n patients with the NADPH oxidase deficiency chronic granulomatous disease, who require antibiotic an

186 The treatment of chronic granulomatous disease with conventional allogene

187 Defects in oxidase function result in chronic granulomatous disease with hallmark recurrent mi

188 severe G6PD deficiency can be a phenocopy of chronic granulomatous disease with regard to the cellula

189 Mice with chronic granulomatous disease (X-CGD mice) generated by

190 sing an established murine model of X-linked chronic granulomatous disease (X-CGD) created by homolog

191 or) was used in a clinical trial of X-linked chronic granulomatous disease (X-CGD) gene therapy to ac

192 ietic stem cells from patients with X-linked chronic granulomatous disease (X-CGD) give rise to X-CGD

193 ratory previously demonstrated that X-linked chronic granulomatous disease (X-CGD) mice develop exagg

194 piratory burst (phagocyte oxidase)-deficient chronic granulomatous disease (X-CGD) mice.

195 ) for conditioning of wild-type and X-linked chronic granulomatous disease (X-CGD) mice.

196 The X-linked form of chronic granulomatous disease (X-CGD) results from mutat

197 or this model, because in mice with X-linked chronic granulomatous disease (X-CGD) that lack oxidase

198 atory-burst oxidase cytochrome b-558, mimics chronic granulomatous disease (X-CGD) to study the role

199 m cells (iPSCs) from a patient with X-linked chronic granulomatous disease (X-CGD), a defect of neutr

200 The X-linked form of chronic granulomatous disease (X-CGD), an inherited defi

201 In HSPCs from patients with X-linked chronic granulomatous disease (X-CGD), caused by mutatio

202 mpartment in patients and mice with X-linked chronic granulomatous disease (X-CGD).

203 ciencies of which cause the X-linked form of chronic granulomatous disease (X-CGD).

204 tory burst-deficient gp91(phox)-/- (X-linked chronic granulomatous disease [X-CGD]) mice and inducibl

205 PMNs from individuals with X-linked chronic granulomatous disease (XCGD) do not produce ROS,